The nation's #1 conference on practical psychopharmacology, offering more practical psychopharmacology content than any other conference and empowering the highest standard in mental health care.
While the medical community has long recognized ADHD’s impact, new scientific breakthroughs are revolutionizing how we conceptualize this complex neurodevelopmental disorder.
This research, one of the most comprehensive to date with over 140,000 participants across four states, challenges our previous understanding of ADHD as primarily a childhood condition.
Attention-deficit/hyperactivity disorder (ADHD) affects 5% of children world-wide. Of these, two-thirds continue to have impairing symptoms of ADHD into adulthood. Although a large literature implicates structural brain differences of the disorder, it is not clear if adults with ADHD have similar neuroanatomical differences as those seen in children with recent reports from the large ENIGMA-ADHD consortium finding structural differences for children but not for adults. This paper uses deep learning neural network classification models to determine if there are neuroanatomical changes in the brains of children with ADHD that are furthermore observed for adult ADHD, and vice versa. We found that structural MRI data can significantly separate ADHD from control participants for both children and adults. Consistent with the prior reports from ENIGMA-ADHD, prediction performance and effect sizes were better for the child than the adult samples. The model trained on adult samples significantly predicted ADHD in the child sample, suggesting that our model learned anatomical features that are common to ADHD in childhood and adulthood. These results support the continuity of ADHD’s brain differences from childhood to adulthood. In addition, our work demonstrates a novel produce use of of neural network classification models to test hypotheses about developmental continuity.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the leading experience, we recommend you employ a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Furthermore, visual representations like the one above help us fully grasp the concept of Adhd Studies 2021.
From foundational psychopharmacology to advanced clinical practice, the Psych Congress portfolio delivers transformative education designed to grow with you. With a robust portfolio of educational events, Psych Congress supports mental health clinicians from training to mastery. No matter where you are in your career, Psych Congress meets you there.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the finest experience, we recommend you utilize a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
In January 2025, a landmark study published in the American Psychiatric Association Journal Psychiatric Research and Clinical Practice revealed surprising shifts in ADHD diagnosis rates, showing a significant increase among adults since 2020. ( Source: www.psychiatry.org ).
Attention-deficit/hyperactivity disorder (ADHD; as well known as hyperkinetic disorder) is a common neurodevelopmental condition that affects children and adults worldwide. ADHD has a predominantly genetic aetiology that involves common and rare genetic variants. Some environmental correlates of the disorder have been discovered but causation has been difficult to establish. The heterogeneity of the condition is evident in the diverse presentation of symptoms and levels of impairment, the numerous co-occurring mental and physical conditions, the various domains of neurocognitive impairment, and extensive minor structural and functional brain differences. The diagnosis of ADHD is reliable and valid when evaluated with standard diagnostic criteria. Curative treatments for ADHD do not exist but evidence-based treatments substantially reduce symptoms and/or functional impairment. Medications are effective for core symptoms and are usually well tolerated. Some non-pharmacological treatments are valuable, especially for improving adaptive functioning. Clinical and neurobiological research is ongoing and could lead to the creation of personalized diagnostic and therapeutic approaches for this disorder.
